Takeda Aims To Turn Brintellix Into CNS Cornerstone, Arm-In-Arm With Lundbeck
Executive Summary
Multimodal antidepressant Brintellix (vortioxetine) represents Takeda’s first shot at a major depression launch and the future for Lundbeck as blockbuster Lexapro fades into the distance. Time will tell if the partners have what it takes to compete in a highly genericized market; evidence of cognitive benefits could help.